Viropro subsidiary BPD expands lab services

By Alexandria Pesic

- Last updated on GMT

Related tags: Subsidiary, Biotechnology

Biologics Process Development, a wholly-owned subsidiary of Californian contract research organisation (CRO), Viropro, has announced it is to double the size of its bioprocess and scale-up laboratory.

The company, which specialises in providing contract laboratory services for the biotech and biopharma industries, claims the expansion will allow it to better serve the needs of existing clients who demand larger processing volumes, whilst potentially attracting new business.

In addition, the company has announced various changes at boardroom level, including the appointment of former BioProcess Technology Consultants (BTC) founder, Howard Levine and former vice president of EU and US pharmaceutical development at Japanese firm, Santen, Pete Fernandes.

Fernandes was previously involved in both the technical and strategic management of early and late-stage drug development of recombinant-derived biologicals and small molecules.

Meanwhile, prior to founding BTC, Levine held positions in process development at both Genentech and Amgen.

Share deal

Virorpro acquired BPD in 2010 after brokering a deal which saw BPD’s Indian owners, Intas, receive 90 million shares in return. The companies planned to integrate their activities in the area of biotech contract research and manufacturing services (CRAM).

Speaking at the time of the deal, Virorpro president Serge Beausoleil, said: “Both Viropro and Intas share a common goal of creating a global biotech CRAMS footprint that utilises the strengths of each of its constituent companies and partners towards providing a seamless clone-to-clinic offering.”

Business plan

News of BPD’s lab expansion comes soon after parent company Viropro released an update of its long term business plan, claiming its mission is to “become the premier provider of outsourced research, development and manufacturingservices for the biopharmaceutical industry.”

The company said the market for biopharmaceutical drugs stood at an estimated $75bn (€53bn), with the rapidly developing Japanese and European markets set to exceed $2bn (€1.4bn) by 2015, driven primarily by an aging population.

Related news

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more